References
- Tragiannidis A, Gkampeta A, Vousvouki M, et al. Antifungal agents and the kidney: pharmacokinetics, clinical nephrotoxicity, and interactions. Expert Opin Drug Saf. 2021;1–14. DOI:https://doi.org/10.1080/14740338.2021.1922667
- Luke DR, Tomaszewski K, Damle B, et al. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (sbecd). J Pharm Sci. 2010;99(8):3291–3301.
- Kim SH, Kwon JC, Park C, et al. Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether beta-cyclodextrin in haematological patients with renal impairment. Mycoses. 2016;59(10):644–651.
- Myrianthefs P, Markantonis SL, Evaggelopoulou P, et al. Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study. Int J Antimicrob Agents. 2010;35(5):468–472.
- Lilly CM, Welch VL, Mayer T, et al. Evaluation of intravenous voriconazole in patients with compromised renal function. BMC Infect Dis. 2013;13(14). DOI:https://doi.org/10.1186/1471-2334-13-14
- Oude Lashof AM, Sobel JD, Ruhnke M, et al. Safety and tolerability of voriconazole in patients with baseline renal insufficiency and candidemia. Antimicrob Agents Chemother. 2012;56(6):3133–3137.
- Neofytos D, Lombardi LR, Shields RK, et al. Administration of voriconazole in patients with renal dysfunction. Clin Infect Dis. 2012;54(7):913–921.
- Alvarez-Lerma F, Allepuz-Palau A, Garcia MP, et al. Voriconazole study group in critically Ill P: impact of intravenous administration of voriconazole in critically ill patients with impaired renal function. J Chemother. 2008;20(1):93–100.
- Abel S, Allan R, Gandelman K, et al. Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects: two prospective, multicentre, open-label, parallel-group volunteer studies. Clin Drug Investig. 2008;28(7):409–420.
- von Mach MA, Burhenne J, Weilemann LS. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin Pharmacol. 2006;6(6). DOI:https://doi.org/10.1186/1472-6904-6-6
- Hafner V, Czock D, Burhenne J, et al. Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration. Antimicrob Agents Chemother. 2010;54(6):2596–2602.
- Luke DR, Wood ND, Tomaszewski KE, et al. Pharmacokinetics of sulfobutylether-beta-cyclodextrin (sbecd) in subjects on hemodialysis. Nephrol Dial Transplant. 2012;27(3):1207–1212.
- Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin b followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet. 2005;366(9495):1435–1442.
- Alvarez-Lerma F, Nicolas-Arfelis JM, Rodriguez-Borregan JC, et al. Clinical use and tolerability of voriconazole in the treatment of fungal infections in critically ill patients. J Chemother. 2005;17(4):417–427.
- Muldrew KM, Maples HD, Stowe CD, et al. Intravenous voriconazole therapy in a preterm infant. Pharmacotherapy. 2005;25(6):893–898.
- Shohab D, Hussain I, Khawaja A, et al. Primary renal aspergillosis and xanthogranulomatous pyelonephritis in an immuno-competent toddler. J Coll Physicians Surg Pak. 2014;24(Suppl 2):S101–103.